Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has announced that data on LUPKYNIS™ (voclosporin) will be presented at the 59th European Renal Association (ERA) Congress and the European Congress of Rheumatology (EULAR) 2022. The events will showcase the results of the ongoing AURORA 2 continuation study, focusing on the long-term safety of LUPKYNIS for lupus nephritis. LUPKYNIS is notable as the first FDA-approved oral treatment for active lupus nephritis, with a dual mechanism of action aimed at stabilizing kidney function.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported net revenues of $21.6 million for Q1 2022, significantly up from $914,000 in Q1 2021, driven by strong demand for LUPKYNIS following its FDA approval in January 2021. The company maintains its revenue guidance of $115-$135 million for 2022, reflecting a growth of over 150-200% compared to 2021. Despite a net loss of $37.6 million for the quarter, improvements in patient start forms and an upcoming EMA review for LUPKYNIS are promising milestones. Aurinia's cash reserves stood at $418.8 million as of March 31, 2022.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced a change to the dial-in numbers for its first-quarter financial and operational results conference call on May 10, 2022. The updated numbers are (866) 682-6100 / (862) 298-0702 for U.S. and Canada participants. Additionally, an audio webcast will be accessible via the 'Investors' section on Aurinia's website, with a replay available following the event. Aurinia is known for its FDA-approved oral therapy for treating active lupus nephritis, focusing on serious diseases with high unmet medical needs.

Aurinia Pharmaceuticals (NASDAQ: AUPH) will announce its financial and operational results for Q1 2022 on May 10, 2022, before the market opens. The management team will conduct a conference call/webcast at 8:30 am ET to discuss the results and provide a business update. Interested parties can participate by dialing +1-877-407-9170 or accessing the audio webcast via Aurinia’s corporate website. Aurinia is dedicated to developing therapies for serious diseases, having introduced the first FDA-approved oral treatment for lupus nephritis in January 2021.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is sponsoring charitable grants to expand community-focused patient navigator programs for individuals with systemic lupus erythematosus (SLE) and lupus nephritis (LN). This initiative aims to eliminate care barriers, particularly in underserved populations. Grants of up to $50,000 will be awarded to U.S.-based organizations to enhance patient education and access to treatment. In its first year, Aurinia distributed $250,000 to five programs, showing significant improvements in patient care and adherence.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced new analyses of LUPKYNIS™ (voclosporin) to be presented at the 2022 National Kidney Foundation Spring Clinical Meetings in Boston from April 6-10, 2022. The studies aim to expand the understanding of LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis. Presentations will include findings on the drug's efficacy, a prospective observational registry, and improvements in disease impact. The research underscores Aurinia's commitment to autoimmune disease therapeutics.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its executive management team's participation in two investor conferences. The Cowen 42nd Annual Virtual Healthcare Conference is scheduled for March 9, 2022, at 2:50 p.m. ET, while the Oppenheimer’s 32nd Annual Healthcare Conference will take place on March 16, 2022, at 1:20 p.m. ET. Interested parties can access the live webcasts on the Aurinia corporate website under the Investors section.

Aurinia is focused on treating serious diseases, having launched LUPKYNIS™, the first FDA-approved oral therapy for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a 60% increase in Q4 2021 net revenue to $23.4 million and a full-year revenue of $45.6 million. The company achieved notable growth in LUPKYNIS patient starts and maintained a strong cash position of $466.1 million as of December 31, 2021. For 2022, Aurinia projects net revenue guidance of $115-$135 million, driven by positive results from the AURORA 2 study. With confirmed payor coverage exceeding 90% in the U.S., Aurinia is well-positioned for ongoing progress amid a robust product launch.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its fourth quarter and year-end 2021 financial results on February 28, 2021, before markets open. A conference call/webcast will be held at 8:30 am ET to discuss the results and the company's outlook for 2022. Aurinia focuses on therapies for serious diseases with high unmet needs, having launched the first FDA-approved oral treatment for active lupus nephritis in January 2021.